Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.

Literature DB >> 22798970

Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.

Fengfu Li¹, Bernard Hurley, Yun Liu, Brian Leonard, May Griffith.

Abstract

Bevacizumab (Avastin(®)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres fabricated from poly(DL-lactide-co-glycolide) and poly(ethylene glycol)-b-poly(D,L-lactic acid), respectively. The drug release rate could be adjusted by alteration of the drug/polymer ratio. The use of such nano- and microspheres as bevacizumab delivery vehicles may improve the treatment of wet AMD.

Entities: Chemical Disease Gene Species

Keywords: Bevacizumab; age-related macular degeneration; and controlled release.; microspheres; nanospheres

Year: 2012 PMID： 22798970 PMCID： PMC3394187 DOI： 10.2174/1874364101206010054

Source DB: PubMed Journal: Open Ophthalmol J ISSN： 1874-3641

29 in total

Review 1. Colloidal carriers for ophthalmic drug delivery.

Authors: Rubiana Mara Mainardes; Maria Cristina Cocenza Urban; Priscila Oliveira Cinto; Najeh Maissar Khalil; Marco Vinícius Chaud; Raul Cesar Evangelista; Maria Palmira Daflon Gremiao
Journal: Curr Drug Targets Date: 2005-05 Impact factor: 3.465

Review 2. Multifunctional nanocarriers.

Authors: Vladimir P Torchilin
Journal: Adv Drug Deliv Rev Date: 2006-09-28 Impact factor: 15.470

Review 3. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems.

Authors: Catarina Pinto Reis; Ronald J Neufeld; António J Ribeiro; Francisco Veiga
Journal: Nanomedicine Date: 2006-06 Impact factor: 5.307

Review 4. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.

Authors: Catarina Pinto Reis; Ronald J Neufeld; António J Ribeiro; Francisco Veiga
Journal: Nanomedicine Date: 2006-03 Impact factor: 5.307

5. A new absorbable suture.

Authors: E J Frazza; E E Schmitt
Journal: J Biomed Mater Res Date: 1971

6. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.

Authors: Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman
Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079

7. Expression of liver-specific functions by rat hepatocytes seeded in treated poly(lactic-co-glycolic) acid biodegradable foams.

Authors: V Hasirci; F Berthiaume; S P Bondre; J D Gresser; D J Trantolo; M Toner; D L Wise
Journal: Tissue Eng Date: 2001-08

8. Controlled delivery of ganciclovir to the retina with drug-loaded Poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis.

Authors: Sridhar Duvvuri; Kumar G Janoria; Dhananjay Pal; Ashim K Mitra
Journal: J Ocul Pharmacol Ther Date: 2007-06 Impact factor: 2.671

9. A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.

Authors: N Melda Yenerel; Umut A Dinc; Ebru Gorgun
Journal: J Ocul Pharmacol Ther Date: 2008-06 Impact factor: 2.671

10. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.

Authors: Karen G Carrasquillo; Joseph A Ricker; Ioannis K Rigas; Joan W Miller; Evangelos S Gragoudas; Anthony P Adamis
Journal: Invest Ophthalmol Vis Sci Date: 2003-01 Impact factor: 4.799

20 in total

Review 1. Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.

Authors: Eric Wakshull; Valerie Quarmby; Hanns-Christian Mahler; Hongwen Rivers; Dhananjay Jere; Meg Ramos; Piotr Szczesny; Karoline Bechtold-Peters; Sharmila Masli; Swati Gupta
Journal: AAPS J Date: 2017-08-09 Impact factor: 4.009

Review 2. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors: Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal: Adv Drug Deliv Rev Date: 2018-01-13 Impact factor: 15.470

Review 3. Nanotechnology in retinal drug delivery.

Authors: Sibo Jiang; Yesenia L Franco; Yan Zhou; Jianjun Chen
Journal: Int J Ophthalmol Date: 2018-06-18 Impact factor: 1.779

Review 4. Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System.

Authors: Md Habban Akhter; Irfan Ahmad; Mohammad Y Alshahrani; Alhanouf I Al-Harbi; Habibullah Khalilullah; Obaid Afzal; Abdulmalik S A Altamimi; Shehla Nasar Mir Najib Ullah; Abhijeet Ojha; Shahid Karim
Journal: Gels Date: 2022-01-28

5. Multiplexed Analysis of the Cellular Uptake of Polymeric Nanocarriers.

Authors: Dheeraj K Agrohia; Peidong Wu; Uyen Huynh; S Thayumanavan; Richard W Vachet
Journal: Anal Chem Date: 2022-05-25 Impact factor: 8.008

6. Nanomedicines for Endothelial Disorders.

Authors: Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal: Nano Today Date: 2015-12-01 Impact factor: 20.722

7. Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide.

Authors: Ron B Shmueli; Masayuki Ohnaka; Akiko Miki; Niranjan B Pandey; Raquel Lima e Silva; Jacob E Koskimaki; Jayoung Kim; Aleksander S Popel; Peter A Campochiaro; Jordan J Green
Journal: Biomaterials Date: 2013-07-10 Impact factor: 12.479